XENTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Stats
本日の出来高	0.00
平均出来高	438 704
時価総額	0.00
EPS	$-0.850 ( 2022-05-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.54
ATR14	$0.137 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-13	Meier Richard A	Sell	57 230	Common Stock
2022-05-13	Meier Richard A	Sell	65 759	Common Stock
2022-05-13	Meier Richard A	Sell	40 607	Common Stock
2022-05-13	Meier Richard A	Sell	34 000	Stock Options (Right to buy)
2022-05-13	Meier Richard A	Sell	74 852	Stock Options (Right to buy)

INSIDER POWER
-100.00
Last 98 transactions
Buy: 482 629 \| Sell: 874 745

ボリューム相関

長: 0.54 (weak)

短: 0.61 (weak)

Signal:(64.961) Neutral

Intersect Ent Inc 相関

10 最も正の相関
GLLI	0.937
ACAB	0.933
FEXD	0.929
APMI	0.929
FNVT	0.929
AVAC	0.928
CBRG	0.926
CIIG	0.925
BRIV	0.923
ALSA	0.921

10 最も負の相関
EVLO	-0.925
NCBS	-0.923
IRBT	-0.922
CREG	-0.92
DRUG	-0.917
ATAI	-0.916
CRON	-0.913
ARQQ	-0.912
BLU	-0.911
VFF	-0.91

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Intersect Ent Inc 相関 - 通貨/商品

-0.61
( weak negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.65
( weak negative )

0.07
( neutral )

0.70
( moderate )

Intersect Ent Inc 財務諸表

Annual	2021
収益:	$106.75M
総利益:	$76.74M (71.89 %)
EPS:	$-4.80

FY	2021
収益:	$106.75M
総利益:	$76.74M (71.89 %)
EPS:	$-4.80

FY	2020
収益:	$80.55M
総利益:	$50.25M (62.38 %)
EPS:	$-2.22

FY	2019
収益:	$109.14M
総利益:	$87.37M (80.05 %)
EPS:	$-1.370

Financial Reports:

No articles found.

Intersect Ent Inc

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.